Consolidated revenue and net profit for the quarter ended December 31, 2024, showed modest year-over-year growth, with continued focus on the pharmaceutical and healthcare segment. Statutory auditors issued unmodified review reports.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.